Response to Caravita di Toritto and Rago
- PMID: 36300846
- DOI: 10.1111/ejh.13887
Response to Caravita di Toritto and Rago
Comment on
-
Response to "Conditioning with melphalan (Mel) 200 mg/m2 and subsequent autologous stem cell transplantation improves progression free survival and overall survival in elderly multiple myeloma patients compared to standard of care".Eur J Haematol. 2023 Feb;110(2):221. doi: 10.1111/ejh.13888. Epub 2022 Nov 8. Eur J Haematol. 2023. PMID: 36300853 No abstract available.
References
REFERENCES
-
- Sirohi R, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25:533-539.
-
- Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51-54.
-
- Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37(10):917-922.
-
- Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39:279-283.
-
- Rago A, Annibali O, Tomarchio V, et al. Autologous stem cell transplantation in multiple myeloma patients over 70 years: a GIMEMA Lazio working group experience in a retrospective case-control study. Eur J Haematol. 2022;109(3):250-256.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources